In the NINDS r-tPA trial (National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator),16,101 exclusion for rapidly improving symptoms aimed to avoid treating transient ischemic attacks. The gene discussed is PLAT; the disease is transient ischemic attack.